Systemic therapy breakthroughs in the management of brain metastases: A new era for HER2-positive breast cancer
Cancer Treatment and Research Communications · 2025 · 45 · 100997
DOI: 10.1016/j.ctarc.2025.100997 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Martina Parenza Arenhardt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncoclínicas&Co - Medica Scientia Innovation Research (MEDSIR), São Paulo 04542-390, Brazil. Electronic address: tinaparenza@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
HER2-positive subtype accounts for 15-20 % of metastatic breast cancer (mBC) cases and is associated with a high incidence of brain metastases (BMs), which affects 35-50 % of the patients, contributing to poor outcomes. Although HER2-targeted therapies have significantly improved overall survival (OS), central nervous system (CNS) involvement remains a significant challenge due to the blood-brain barrier (BBB), which limits systemic treatment efficacy. The advent of antibody-drug conjugates (ADCs) has introduced promising therapeutic options with demonstrated CNS activity. This narrative review synthesizes current evidence on systemic treatments for HER2-positive BMs. A comprehensive literature search included PubMed, ASCO, ESMO, and NCCN guidelines, as well as ongoing trials from ClinicalTrials.gov. Until recently, the HER2CLIMB regimen-combining tucatinib, trastuzumab, and capecitabine-was the most effective option for CNS disease control, achieving a median CNS progression-free survival (PFS) of 9.9 months. However, recent trials highlight the transformative impact of antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), in this clinical setting. Pooled analyses from the DESTINY-Breast trials reported intracranial overall response rates (ICORR) of 45.5 % in untreated and 45.2 % in treated BMs. Smaller studies, such as DEBBRA and TUXEDO-1, demonstrated ICORRs of 66.7 % and 73.3 %, respectively, with TUXEDO-1 reporting a median PFS of 14 months. The phase III/IV DESTINY-Breast12 trial further validated T-DXd's efficacy in active BMs, achieving a CNS PFS of 17.3 months and an ICORR of 62.3 %, with the highest responses (82.6 %) in untreated BMs. The current analysis reviews the available data on managing brain metastasis and highlights T-DXd's potential to redefine treatment strategies. It also discusses unanswered questions, such as the role of radiotherapy in asymptomatic disease and the evolving landscape of ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncoclínicas&Co - Medica Scientia Innovation Research (MEDSIR), São Paulo 04542-390, Brazil. Electronic address: tinaparenza@gmail.com.
- Oncoclínicas&Co - Medica Scientia Innovation Research (MEDSIR), São Paulo 04542-390, Brazil.
- Oncoclínicas&Co - Medica Scientia Innovation Research (MEDSIR), São Paulo 04542-390, Brazil; Department of Internal Medicine at the Federal University of Minas Gerais, Brazil.
Zitieren
APA
Arenhardt, M. P., Vieira, C. M., & Nogueira-Rodrigues, A. (2025). Systemic therapy breakthroughs in the management of brain metastases: A new era for HER2-positive breast cancer. Cancer Treatment and Research Communications, 45, 100997. https://doi.org/10.1016/j.ctarc.2025.100997
Vancouver
Arenhardt MP, Vieira CM, Nogueira-Rodrigues A. Systemic therapy breakthroughs in the management of brain metastases: A new era for HER2-positive breast cancer. Cancer Treatment and Research Communications. 2025;45:100997. doi:10.1016/j.ctarc.2025.100997
BibTeX
@article{Arenhardt2025,
author = {Arenhardt, Martina Parenza and Vieira, Carolina Martins and Nogueira-Rodrigues, Angélica},
title = {Systemic therapy breakthroughs in the management of brain metastases: A new era for HER2-positive breast cancer},
journal = {Cancer Treatment and Research Communications},
year = {2025},
volume = {45},
pages = {100997},
doi = {10.1016/j.ctarc.2025.100997}
}
EUVIMED